Monoclonal Antibody Therapy in Treating Patients With Advanced or Recurrent Lymphoma

Completed · Phase 1

Conditions studied: Lymphoma, Small Intestine Cancer

In brief

RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. PURPOSE: Phase I trial to study the effectiveness of monoclonal antibody therapy in treating patients who have advanced or recurrent lymphoma.

Key facts

Study ID

NCT00006009

Run by

Stanford University

Starts

2001-04-01

Expected to finish

2003-10-01

Last updated by the study team

2013-05-15

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Stanford University Medical Center — Stanford, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.